ArticleJHLT open2026
Balancing cancer recurrence risk and respiratory mortality: Immediate listing for lung transplantation following HCC therapy.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignancy usually requires a cancer-free interval before lung transplantation, although individualized exceptions are allowed based on tumor biology and recurrence risk. We report a case of urgent bilateral lung transplantation performed 30 days after curative-intent therapy for hepatocellular carcinoma (HCC) in a 66-year-old man with rapidly progressive idiopathic pulmonary fibrosis. Over 52 months of MRI surveillance, there was no evidence of HCC recurrence. The patient ultimately died 4 years after transplantation from advanced chronic lung allograft dysfunction. This case illustrates that, in exceptionally selected patients with localized HCC and documented response to locoregional therapy, expedited lung transplant listing may be clinically and ethically justified when near-term respiratory mortality outweighs the anticipated risk of cancer recurrence. Such decisions should remain individualized and multidisciplinary rather than broadly generalizable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.